These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 15671527

  • 21. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
    Chatzistamou I, Schally AV, Sun B, Armatis P, Szepeshazi K.
    Br J Cancer; 2000 Oct; 83(7):906-13. PubMed ID: 10970693
    [Abstract] [Full Text] [Related]

  • 22. Antitumoral activity of bombesin analogues on small cell lung cancer xenografts: relationship with bombesin receptor expression.
    Thomas F, Arvelo F, Antoine E, Jacrot M, Poupon MF.
    Cancer Res; 1992 Sep 15; 52(18):4872-7. PubMed ID: 1325285
    [Abstract] [Full Text] [Related]

  • 23. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
    Papadia A, Schally AV, Halmos G, Varga JL, Seitz S, Buchholz S, Rick F, Zarandi M, Bellyei S, Treszl A, Szalontay L, Lucci JA.
    Horm Metab Res; 2011 Oct 15; 43(11):816-20. PubMed ID: 22009378
    [Abstract] [Full Text] [Related]

  • 24. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
    Muñoz-Moreno L, Arenas MI, Schally AV, Fernández-Martínez AB, Zarka E, González-Santander M, Carmena MJ, Vacas E, Prieto JC, Bajo AM.
    Int J Cancer; 2013 Feb 15; 132(4):755-65. PubMed ID: 22777643
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
    Plonowski A, Schally AV, Nagy A, Sun B, Szepeshazi K.
    Cancer Res; 1999 Apr 15; 59(8):1947-53. PubMed ID: 10213505
    [Abstract] [Full Text] [Related]

  • 26. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
    Engel JB, Keller G, Schally AV, Halmos G, Hammann B, Nagy A.
    Clin Cancer Res; 2005 Mar 15; 11(6):2408-15. PubMed ID: 15788692
    [Abstract] [Full Text] [Related]

  • 27. Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical.
    Santos-Cuevas CL, Ferro-Flores G, Arteaga de Murphy C, Ramírez Fde M, Luna-Gutiérrez MA, Pedraza-López M, García-Becerra R, Ordaz-Rosado D.
    Int J Pharm; 2009 Jun 22; 375(1-2):75-83. PubMed ID: 19393305
    [Abstract] [Full Text] [Related]

  • 28. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095).
    Radulovic S, Miller G, Schally AV.
    Cancer Res; 1991 Nov 01; 51(21):6006-9. PubMed ID: 1682040
    [Abstract] [Full Text] [Related]

  • 29. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
    Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K, O'Byrne K, Cai RZ.
    Br J Cancer; 1994 Nov 01; 70(5):886-92. PubMed ID: 7947094
    [Abstract] [Full Text] [Related]

  • 30. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin.
    Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino AL, Varga JL.
    Proc Natl Acad Sci U S A; 2003 Dec 23; 100(26):15836-41. PubMed ID: 14660794
    [Abstract] [Full Text] [Related]

  • 31. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells.
    Levine L, Lucci JA, Pazdrak B, Cheng JZ, Guo YS, Townsend CM, Hellmich MR.
    Cancer Res; 2003 Jul 01; 63(13):3495-502. PubMed ID: 12839933
    [Abstract] [Full Text] [Related]

  • 32. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.
    Lu S, Lee J, Revelo M, Wang X, Lu S, Dong Z.
    Clin Cancer Res; 2007 Oct 01; 13(19):5692-702. PubMed ID: 17908958
    [Abstract] [Full Text] [Related]

  • 33. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
    Klukovits A, Schally AV, Szalontay L, Vidaurre I, Papadia A, Zarandi M, Varga JL, Block NL, Halmos G.
    Cancer; 2012 Feb 01; 118(3):670-80. PubMed ID: 21751186
    [Abstract] [Full Text] [Related]

  • 34. Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma.
    Kanashiro CA, Schally AV, Varga JL, Hammann B, Halmos G, Zarandi M.
    Cancer Lett; 2005 Aug 26; 226(2):123-31. PubMed ID: 16039952
    [Abstract] [Full Text] [Related]

  • 35. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K, Schally AV, Cai RZ, Radulovic S, Milovanovic S, Szoke B.
    Cancer Res; 1991 Nov 01; 51(21):5980-6. PubMed ID: 1682039
    [Abstract] [Full Text] [Related]

  • 36. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
    Szepeshazi K, Schally AV, Treszl A, Seitz S, Halmos G.
    Anticancer Drugs; 2008 Apr 01; 19(4):349-58. PubMed ID: 18454045
    [Abstract] [Full Text] [Related]

  • 37. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
    Halmos G, Schally AV.
    Proc Natl Acad Sci U S A; 1997 Feb 04; 94(3):956-60. PubMed ID: 9023364
    [Abstract] [Full Text] [Related]

  • 38. New treatment approaches for prostate cancer based on peptide analogues.
    Stangelberger A, Schally AV, Djavan B.
    Eur Urol; 2008 May 04; 53(5):890-900. PubMed ID: 18201818
    [Abstract] [Full Text] [Related]

  • 39. [Psi 13,14] bombesin analogues inhibit growth of small cell lung cancerin vitro and in vivo.
    Mahmoud S, Staley J, Taylor J, Bogden A, Moreau JP, Coy D, Avis I, Cuttitta F, Mulshine JL, Moody TW.
    Cancer Res; 1991 Apr 01; 51(7):1798-802. PubMed ID: 1848479
    [Abstract] [Full Text] [Related]

  • 40. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers.
    Stangelberger A, Schally AV, Letsch M, Szepeshazi K, Nagy A, Halmos G, Kanashiro CA, Corey E, Vessella R.
    Int J Cancer; 2006 Jan 01; 118(1):222-9. PubMed ID: 16003723
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.